{"id":"NCT00160524","sponsor":"UCB Pharma SA","briefTitle":"A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]","officialTitle":"A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed 4-weekly), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Completed Studies CDP870-031 or CDP870-032","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-07","primaryCompletion":"2012-08","completion":"2012-08","firstPosted":"2005-09-12","resultsPosted":"2013-10-10","lastUpdate":"2018-08-01"},"enrollment":596,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Certolizumab Pegol (CDP870)","otherNames":["Cimzia","CDP870","CZP"]}],"arms":[{"label":"Certolizumab Pegol","type":"EXPERIMENTAL"}],"summary":"An open-label follow-on safety study of CDP870 (400 mg every 4 weeks) in patients with Crohn's Disease who have completed a 26-week blinded study (CDP870-031 \\[NCT00152490\\] or CDP870-032 \\[NCT00152425\\]).","primaryOutcome":{"measure":"Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of the Study CDP870-033 (up to 84 Months)","timeFrame":"Up to 84 months from Study Entry (Week 0) to the Study End (Week 364) and the Safety Follow-up (Week 374)","effectByArm":[{"arm":"Certolizumab Pegol","deltaMin":88.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":206,"countries":["United States","Australia","Austria","Belarus","Belgium","Bulgaria","Canada","Czechia","Denmark","Estonia","Georgia","Germany","Hong Kong","Hungary","Israel","Italy","Latvia","Lithuania","New Zealand","Norway","Poland","Russia","Serbia","Singapore","Slovenia","South Africa","Spain","Sweden","Ukraine"]},"refs":{"pmids":["20117244","28410341","27494777"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":240,"n":595},"commonTop":["Crohn's disease","Nasopharyngitis","Abdominal pain","Urinary tract infection","Influenza"]}}